Cologic® colorectal cancer test

The Cologic® test sets a new standard for determining your risk of colorectal cancer. A positive Cologic test result means that your risk of colorectal cancer is increased by up to 50-fold compared to a person with a negative test result*. In comparison, your risk is only 1.5-fold higher if you have had a close family member diagnosed with colorectal cancer. This is why Cologic is revolutionary in its ability to identify risk.

Cologic is the result of nearly ten years of research and development at PDI. The Cologic test measures GTA-446 (a protective metabolite in your blood) using an instrument called a mass spectrometer. A simple blood draw is all you need – no bowel preparation, no fasting, and no fecal collection. If GTA-446 levels are too low, you have an increased risk of colorectal cancer – it is that simple.

A physician should review all test results. People with positive Cologic results should adhere to current colorectal cancer screening guidelines. People with a negative result should be retested every two years.

For more detailed technical information on the Cologic test, we invite you to visit our Healthcare Professionals pages or our list of colorectal cancer publications.

Please visit our Contact Us page for information on how to access the Cologic test in your area.

*Based on the difference in predicted CRC incidence rates between subjects with Cologic® positive and negative test results and Canadian Cancer Statistics 2012.


The Cologic® test is intended for use in risk assessment and monitoring; it is not a standalone diagnostic test, and is not a screening test for colon cancer.

PanaSee™ pancreatic cancer test